ObsEva to Present at the H.C. Wainwright BioConnect 2022 Conference

Rhea-AI Summary

ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company focused on women's reproductive health, announced a corporate update presentation during the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The presentation will be available on-demand starting at 7 a.m. EST on January 10, 2022. Additionally, a webcast will be accessible after the event on the company's website under Events Calendar. ObsEva is advancing therapies for uterine fibroids, endometriosis, and preterm labor.

GENEVA, Switzerland January 3, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright BioConnect Conference, to be held January 10-13, 2022.

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. EST on Monday, January 10, 2022.

A webcast can be accessed here and will also be accessible under “Events Calendar” in the investors section of ObsEva’s website, starting Friday, January 14, 2022.

 

About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com

 

For further information, please contact:
CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact
Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617) 435-6602

 

 

Attachment

• Press Release in Pdf

FAQ

What is ObsEva's corporate update about during the H.C. Wainwright BioConnect Conference?

ObsEva will provide a corporate update presentation at the H.C. Wainwright BioConnect Conference from January 10-13, 2022.

When can I access ObsEva's presentation at the conference?

The presentation will be available on-demand starting at 7 a.m. EST on January 10, 2022.

Where can I find the webcast of ObsEva's conference presentation?

The webcast will be accessible on the H.C. Wainwright conference portal and on ObsEva’s website after January 14, 2022.

What is the focus of ObsEva's therapies?

ObsEva develops therapies aimed at improving women's reproductive health, specifically targeting uterine fibroids, endometriosis, and preterm labor.

What is ObsEva's stock symbol?

ObsEva is traded on NASDAQ under the ticker symbol 'OBSV'.